Drawing for REVIR

USPTO serial 97196705

REVIR

Reviewed by CopyMark Law Group

Reg. 6963609Status 700Registered
Filing date
Status date
Registration date
Jan 24, 2023
Examiner
LOVELACE, JAMES B
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with REVIR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Enshan Hong

Enshan Hong MAGSTONE LAW, LLP293 EISENHOWER PARKWAY, SUITE 135LIVINGSTON, NJ 07039UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Scientific research in the field of genetics and genetic engineering; Scientific research consulting in the field of molecular biology, biotechnology, pharmaceutics, immunology and oncology, bacteriology, medical diagnostics and therapy using molecular biological, genetic engineering and biotechnological methods, and scientific research related to screening for pharmaceutically active compounds; Medical and scientific research in the field of molecular biology, biotechnology, pharmaceutics, immunology and oncology, bacteriology, medical diagnostics and therapy using molecular biological, genetic engineering and biotechnological methods, and scientific research related to screening for pharmaceutically active compounds; Scientific research and development; Scientific research and development of diagnostic methods and test processes; Scientific research and development related to technical planning and conducting of projects in the field of the supplying of medicines; Scientific consultancy services in the field of research and development of therapies and medical preparations; Provision of scientific expertise in the nature of scientific study and research in the field of medicine; Scientific research and development for medical and veterinary purposes; Medical and scientific research in the field of treatment of proliferating diseases, cancers, infectious diseases, autoimmune diseases, and neurodegenerative disease, metabolic diseases; Providing medical and scientific research information, consultancy, and advisory services in the fields of treatment of proliferating diseases, cancers, infectious diseases, autoimmune diseases, and neurodegenerative disease; Compiling data for medical and scientific research, clinical trials, and drug admissionACTIVEMay 10, 2021

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 24, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 24, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 8, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 8, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 19, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 5, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 5, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Oct 5, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 5, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 5, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 4, 2022DOCKASSIGNED TO EXAMINER—
Sep 1, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 1, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Sep 1, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 1, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 5, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 3, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance